Printer Friendly

Bayer, Sensyne Health sign two-year collaboration agreement.

Sensyne Health announces that it has signed an initial two-year collaboration agreement with Bayer to accelerate the clinical development of new treatments for cardiovascular disease using Sensyne Health's proprietary clinical AI technology platform. The initial agreement will generate revenues for Sensyne Health of GBP 5 million across the two-year collaboration. Sensyne Health's partner NHS trusts will receive a 4% share of all revenues generated by Sensyne Health under this collaboration. This will be in addition to the NHS Trust's existing shareholdings in Sensyne Health plc. The NHS Long Term Plan identifies cardiovascular disease as a clinical priority and the leading condition where lives can be saved by the NHS over the next 10 years. The disease currently affects 7 million people in the UK and accounts for 1 in 4 premature deaths1. The development of improved treatments for cardiovascular disease is challenging due to the very high cost of clinical trials in this area and investment in cardiovascular drug development has declined over the past twenty years as a result2. Real world evidence from Sensyne Health's Clinical AI analysis of anonymised patient data has the potential to generate new insights that could improve patient outcomes, support clinical staff and accelerate the discovery and development of new medicines to prevent and treat cardiovascular disease including heart failure and stroke.

COPYRIGHT 2019 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Jul 31, 2019
Previous Article:Simmons First National to acquire The Landrum Company.
Next Article:Saia reports Q2 EPS $1.40, consensus $1.32.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters